GILD241206C82000
- 10.55
- 0.000.00%
Gilead Sciences Newsroom
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $99 to $115
Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers
Gilead Sciences (GILD) Gets a Buy From Piper Sandler
Gilead Sciences To Go Ex-Dividend On December 13th, 2024 With 0.77 USD Dividend Per Share
Gilead Sciences Price Target Maintained With a $80.00/Share by Cantor Fitzgerald
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Express News | RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target
Gilead Sciences Hits 4-week High
Gilead Sciences (GILD) Receives a Buy From Jefferies
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $105 to $125
Today's Analyst Rating | Broadcom Price Target Raised to $205 by Citi, Oracle Price Target Raised to $210 by UBS
Express News | Gilead : Leerink Partners Raises Target Price to $99 From $96
Gilead Sciences' Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
BofA Restarts Coverage of 11 Large-cap Biopharmas
Unusual Options Activity: AI, MSTR and Others Attract Market Bets, AI V/OI Ratio Reaches 249.3
Market Falls Wednesday, but Googles Chip Impresses | WST
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel